AstraZeneca should not be overlooked for long
03/04/24 -"While AstraZeneca witnessed a phenomenal turnaround in the last decade, the share price has been quiet in the last two years as sentiment has been impacted by a range of factors including too-high ..."
Pages
65
Language
English
Published on
03/04/24
You may also be interested by these reports :
29/01/26
The 2025 performance delivered on the management’s guidance, backed by a strong showing from the cornerstone immunology medicine Dupixent, newly ...
29/01/26
Roche finished the year on a strong note, backed by healthy performances across key focus areas. Even the 2026 guidance was encouraging. The ...
28/01/26
Lonza’s full-year 2025 CDMO performance surpassed management’s guidance. Top-line growth was driven by strong double-digit increases in Integrated ...
28/01/26
2025 was a year of US tariff threats and drug pricing pressure on the pharma industry, and for AstraZeneca (REDUCE; UK), it started under the cloud ...